[ Price : $8.95]
The agency posts a final guidance that provides recommendations for formal meetings between the agency and sponsors or requestors ...[ Price : $8.95]
FDA finalizes updated guidance for industry outlining current recommendations for demonstrating bioequivalence of generic topical ...[ Price : $8.95]
The House Energy and Commerce Subcommittee on Health plans a hearing 7/15 to examine how FDA can help strengthen U.S. leadership i...[ Price : $8.95]
DTC Perspectives CEO Bob Ehrlich warns that an upcoming FDA proposal to eliminate the adequate provision standard could amount to ...[ Price : $8.95]
Ascelia Pharma pushes back against FDA's recent public release of a Complete Response Letter for its MRI contrast agent Orviglance...[ Price : $8.95]
GSK says its PD-1 inhibitor Jemperli (dostarlimab) achieved the primary endpoint in a registrational Phase 2 trial in patients wit...[ Price : $8.95]
FDA releases a draft guidance detailing its current recommendations for developing psychedelic drug products, providing sponsors w...[ Price : $8.95]
FDA approves a new subcutaneous dosing regimen for Eisai's Alzheimer's disease therapy Leqembi (lecanemab-irmb), allowing patients...